Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hendra monoclonal antibody (MAPP Biopharmaceuticals)
- Development stage
- Preclinical
- Lead developer
- Mapp Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Hendra monoclonal antibodies (Hendra mAbs) are experimental immunotherapies developed by MAPP Biopharmaceuticals for the treatment and prophylaxis of Hendra virus (HeV) infection. These antibodies are designed to neutralize the virus by binding to the viral G (attachment) glycoprotein, which is essential for the virus to latch onto and enter host cells via ephrin-B2 or ephrin-B3 receptors. By blocking this interaction, the antibodies prevent viral replication and spread within the host. This program is part of MAPP's specialized portfolio targeting high-consequence zoonotic viruses, which also includes therapies for Ebola, Marburg, and Nipah viruses. While MAPP has collaborated on the production of the well-known m102.4 antibody, the 'Hendra mAbs' entry in their pipeline represents their ongoing development efforts in the Henipavirus space.
- Other names
- Hendra virus monoclonal antibodyHendra virus neutralizing antibody
02
Targets
NiV-F (Nipah virus fusion glycoprotein)
Beyond the preview
Go deeper on Hendra monoclonal antibody (MAPP Biopharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hendra monoclonal antibody (MAPP Biopharmaceuticals).